NeoStem Closes Underwritten Public Offering Of 5.75 Mln Shares

(RTTNews) - NeoStem, Inc. (NBS), a leader in the emerging cellular therapy industry, Wednesday announced the closing of an underwritten public offering of 5.75 million shares of its common stock. The offering included the fully exercised over-allotment option by the underwriters covering 750,000 shares and was at a price to the public of $7.00 per share.

The gross proceeds to the company were $40.25 million, before deducting underwriting discounts and commissions and other offering expenses payable by the company.

Aegis Capital Corp. acted as sole book-running manager of the offering.